FRI0197 ADHERENCE, SATISFACTION AND FULFILLMENT OF EXPECTATIONS OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS BIOLOGICALS. ARCO STUDY
Background: SB5 is developed as a biosimilar of the reference adalimumab (ADL). Equivalence in pharmacokinetics (PK) and efficacy between SB5-pre-filled syringe (PFS) and ADL-PFS has been demonstrated in a phase I and phase III study.
1,2 The PK equivalence between SB5-PFS and SB5-pre-filled pen (PFP) in healthy subjects has been reported previously. Objectives: To compare the usability and safety of SB5-PFS and SB5-PFP from a phase II study.
Methods:
This was an open-label, single-arm study in patients with rheumatoid arthritis (RA). Patients with RA self-administered a total of 6 injections of 40 mg SB5 every other week; the first two injections were through PFS and the following four injections were through PFP. The primary objective of this study was to demonstrate comparability between PFS (at week 2) and PFP (at week 6) in terms of injection site pain score. Patients completed a pain evaluation questionnaire using an 11-point numeric rating scale at two time points (immediately and 15-30 minutes post-injection) after the first four injections. Equivalence between PFS and PFP was concluded if the 97.5% confidence interval (CI) of the difference in the injection site pain score was contained within the equivalence margin of ±5. Other usability (overall impression and patient preference) and safety endpoints were also measured.
